Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for Darryl Webster
42.60
May 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 16.13 - 50.98
Open     -
Vol / Avg. 0.00/1.20M
Mkt cap 4.65B
P/E     -
Div/yield     -
EPS -0.62
Shares 109.25M
Beta     -
Inst. own 87%
Aug 12, 2015
Q2 2015 Intrexon Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 12, 2015
Intrexon Corp at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Intrexon Corp Earnings Call
May 11, 2015
Q1 2015 Intrexon Corp Earnings Release
Mar 2, 2015
Q4 2014 Intrexon Corp Earnings Call
Mar 2, 2015
Q4 2014 Intrexon Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 82.01% -111.71%
Operating margin -257.39% -97.26%
EBITD margin - -82.78%
Return on average assets 15.95% -15.37%
Return on average equity 21.20% -21.78%
Employees 480 -
CDP Score - -

Address

1750 Kraft Dr Ste 1400
BLACKSBURG, VA 24060-6147
United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. In March 2014, the Company acquired Medistem, Inc. In March 2014, Intrexon Corp acquired laboratory operations in Budapest, Hungary from Codexis, Inc. In August 2014, it acquired Trans Ova Genetics, L.C.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Rick L. Sterling CPA Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Krish S. Krishnan Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Gregory I. Frost Ph.D. Senior Vice President - Health Sector
Age: 43
Bio & Compensation  - Reuters
Thomas Richard Kasser Ph.D. Senior Vice President - Food Sector
Age: 60
Bio & Compensation  - Reuters
Suma M. Krishnan Senior Vice President - Product Development
Age: 49
Bio & Compensation  - Reuters
Nir Nimrodi Senior Vice President - Corporate Development and Environment Sector
Age: 45
Bio & Compensation  - Reuters
Jeffrey T. Perez Senior Vice President — Intellectual Property Affairs
Age: 43
Bio & Compensation  - Reuters
Robert F. Walsh III Senior Vice President - Energy Sector
Age: 56
Bio & Compensation  - Reuters
Darryl Webster Senior Vice President - Intellectual Property
Age: 54
Bio & Compensation  - Reuters